What question did this study set out to answer?

To evaluate the outcomes of different immunosuppression induction strategies in simultaneous heart-kidney transplant (SHKT) recipients.

synapse

⌘+K

April 10, 2026

Contemporary Immunosuppression in Simultaneous Heart–Kidney Transplantation: A United Network for Organ‐Sharing Database Analysis

Key Points

To evaluate the outcomes of different immunosuppression induction strategies in simultaneous heart-kidney transplant (SHKT) recipients.
Data analysis from the United Network for Organ Sharing (UNOS) database.
Comparison of 1-year outcomes across various induction strategies.
Specific focus on patients receiving basiliximab.
1-year outcomes are similar across different induction strategies in SHKT recipients.
Basiliximab is effective for standard-risk SHKT recipients.

Abstract

Contemporary SHKT recipients experience similar 1-year outcomes across induction strategies. Basiliximab may be sufficient for standard-risk SHKT recipients.

Bookmark

Cite This Study

Huang et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8958f6c1944d70ce069bb https://doi.org/https://doi.org/10.1002/phar.70144

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice

2017 · 64 citations